| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a01d7935508cbe002beb151d4efde669 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-60
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4188 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4188
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00 |
| filingDate |
2011-05-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a0d78e4f160766882ced2fd595068ad7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_161af0a09dc2e4c732e0f4f00a5e216c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_41fa933ca7208f00bac62fd0e52e93ae
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b0126a604ccdef49f160175c2ac3f8aa
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_82c4f77f2c2a0f177504109681521f34 |
| publicationDate |
2013-07-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20130081651-A |
| titleOfInvention |
Selective Integrin Inhibitors |
| abstract |
The present invention provides a method for selectively antagonizing α4β1 integrin heterodimers in a subject in need of selective antagonism of α4β1 integrin heterodimers, and preferably in a human subject. The methods of the present invention utilize a conjugate comprising two or more α4β1 small molecule antagonists covalently attached to a biocompatible polymer. These methods of selectively antagonizing α4β1 can be used to regulate both normal and pathological biological processes that are at least partially mediated through α4β1 activity. |
| priorityDate |
2010-04-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |